Epiphora (excessive tearing) and other ocular manifestations related to weekly docetaxel: Underestimated dose-limiting toxicity

Medical Oncology

Volumn 23, Issue 1, 2006, Pages 57-61

  Tsalic, Medy ^a   Gilboa, Michael ^a   Visel, Bela ^a   Miller, Benjamin ^a   Haim, Nissim ^a,b  

^a TECHNION ISRAEL INSTITUTE OF TECHNOLOGY   (Israel)

^b RAMBAM MEDICAL CENTER   (Israel)

Author keywords

Canalicular stenosis; Docetaxel; Drug toxicity; Epiphora

Indexed keywords

ANTINEOPLASTIC AGENT; DOCETAXEL; LANOLIN;

ADULT; AGED; ARTICLE; BLOOD TOXICITY; BREAST CANCER; CANCER CHEMOTHERAPY; CLINICAL ARTICLE; CLINICAL TRIAL; CONJUNCTIVA DISEASE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE SEVERITY; DRUG DOSE REGIMEN; DRUG FATALITY; DRUG INDUCED DISEASE; DRUG WITHDRAWAL; EPIPHORA; EYE SURGERY; EYELID DISEASE; FEMALE; FOLLOW UP; HUMAN; LACRIMAL DUCT OCCLUSION; LUNG NON SMALL CELL CANCER; MADAROSIS; MALE; MEDICAL EXAMINATION; METASTASIS; NASOPHARYNX CARCINOMA; PRIORITY JOURNAL; PROSPECTIVE STUDY; QUESTIONNAIRE; SENSORY DYSFUNCTION; SKIN TOXICITY; TREATMENT DURATION; TREATMENT INDICATION;

ADULT; AGED; ANTINEOPLASTIC AGENTS, PHYTOGENIC; FEMALE; HUMANS; LACRIMAL APPARATUS DISEASES; LACRIMAL DUCT OBSTRUCTION; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; TAXOIDS;

EID: 33646856008     PISSN: 13570560     EISSN: None     Source Type: Journal    
DOI: 10.1385/MO:23:1:57     Document Type: Article

References (10)

1. Esmaeli B, Valero V, Ahmadi A, Booser D. Canalicular stenosis secondary to docetaxel (taxotere): a newly recognized side effect. Ophthalmology 2001;108:994-995.
2. Common Toxicity Criteria. http://ctep.cancer.gov/forms/ CTCAEv3.pdf.
3. Hurwitz JJ. The lacrimal system. Lippincott-Raven Publishers: Philadelphia, PA, 1996; pp. 47-59.
4. Esmaeli B, Ahmasi MA, Rivera E, et al. Docetaxel secretion in tears: association with lacrimal drainage obstruction. Arch Ophthalmol 2002;120:1180-1182.
5. Burstein HJ, Manola J, Younger J, et al. Docetaxel administered on a weekly basis for metastatic breast cancer. J Clin Oncol 2000;18:1212-1219.
6. Esmaeli B, Hortobagyi G, Esteva F, et al. Canalicular stenosis secondary to weekly versus every-3-weeks docetaxel in patients with metastatic breast cancer. Ophthalmology 2002;109:1188-1191.
7. William B Stewart (ed). Surgery of the eyelid orbit and lacrimal system. American Academy of Ophthalmology, 1993.
8. Apple DJ, Rabb MF (eds). Ocular pathology, clinical applications. 4th ed. Mosby Year Book, St. Louis, 1991, pp. 454-493.
9. Gervais R, Ducolone A, Breton JL, et al. Phase II randomised trial comparing docetaxel given every 3 weeks with weekly schedule as second-line therapy in patients with advanced non-small-cell lung cancer (NSCLC). Ann Oncol 2005;16:90-96.
10. Tabernero J, Climent MA, Lluch A, et al. A multicentre, randomised phase II study of weekly or 3-weekly docetaxel in patients with metastatic breast cancer. Ann Oncol 2004;15:1358-1365.